Xia Chen

Xia Chen

Auto-generated profile, based on publicly available information

Xia Chen

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Blood
Verified
Journal Article
Open access
YMYuning Ma
Yuning Ma
XCXia Chen
Xia Chen
MWMengyan Wang
Mengyan Wang
JMJianfen Meng
Jianfen Meng
DZDehao Zhu
Dehao Zhu
QHQiongyi Hu
Qiongyi Hu
Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (AOSD) is characterized by neutrophil activation and a cytokine storm, which can lead to the severe and potentially life-threatening complication of MAS. RNA sequencing revealed that neutrophils may play a distinct role and enhance the innate immunity of patients with AOSD with MAS (AOSD-MAS). In the CpG-induced secondary hemophagocytic lymphohistiocytosis (HLH) model, the depletion of neutrophils significantly reduced cytokine levels with effects comparable with monocyte depletion. Significant enrichment was observed in the type I/II interferon and JAK-STAT pathways in neutrophils from patients with AOSD-MAS. Treatment of 10 patients with refractory AOSD-MAS with ruxolitinib led to the resolution of inflammatory parameters and clinical symptoms. RNA sequencing and ex vivo assays confirmed that ruxolitinib suppressed aberrant NETosis and STAT3/STAT5 signaling. In vivo, PAD4 knockout further confirmed the pathogenic role of NETosis in a secondary HLH model. Moreover, the selective inhibition of STAT3 or STAT5 alleviated systemic inflammation. Ten functional variants were identified in genes related to the JAK-STAT pathway, however, their clinical relevance requires further validation. These findings suggest that ruxolitinib has the potential to facilitate disease remission in patients with refractory AOSD-MAS by broadly inhibiting JAK-STAT signaling and modulating neutrophil activation and NETosis.

9 September 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
XCXia Chen
Xia Chen
QHQiong-Yi Hu
Qiong-Yi Hu
MWMengyan Wang
Mengyan Wang
JJJinchao Jia
Jinchao Jia
JTJialin Teng
Jialin Teng
HLHong-Lei Liu
Hong-Lei Liu